No Data
No Data
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $330
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?
Jefferies Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $329
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Receives CHMP Backing For RNAi Therapy Vutrisiran In Europe
Alnylam, Halozyme Among Latest Firms to Win EU Backing for Drugs
Alnylam's Transthyretin Amyloidosis Drug Gets Positive Opinion From European Medicines Agency